Pfizer Inc. (NYSE:PFE) Shares Acquired by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 219,700 shares of the biopharmaceutical company’s stock after acquiring an additional 22,097 shares during the period. Miracle Mile Advisors LLC’s holdings in Pfizer were worth $5,829,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in PFE. Kwmg LLC increased its position in Pfizer by 6.4% during the fourth quarter. Kwmg LLC now owns 173,153 shares of the biopharmaceutical company’s stock worth $4,594,000 after buying an additional 10,344 shares during the period. PPS&V Asset Management Consultants Inc. increased its stake in Pfizer by 5.6% in the fourth quarter. PPS&V Asset Management Consultants Inc. now owns 15,201 shares of the biopharmaceutical company’s stock valued at $403,000 after purchasing an additional 807 shares during the period. Claro Advisors LLC raised its holdings in shares of Pfizer by 23.1% in the fourth quarter. Claro Advisors LLC now owns 51,413 shares of the biopharmaceutical company’s stock valued at $1,364,000 after buying an additional 9,651 shares during the last quarter. Enterprise Bank & Trust Co boosted its stake in shares of Pfizer by 5.0% during the fourth quarter. Enterprise Bank & Trust Co now owns 12,119 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 576 shares during the period. Finally, Future Financial Wealth Managment LLC grew its holdings in shares of Pfizer by 5.6% during the fourth quarter. Future Financial Wealth Managment LLC now owns 14,133 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 753 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of a number of analyst reports. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.3 %

Shares of PFE stock traded up $0.07 during trading hours on Monday, reaching $26.79. The company had a trading volume of 28,303,215 shares, compared to its average volume of 34,470,996. The stock’s fifty day simple moving average is $26.18 and its 200 day simple moving average is $28.04. The company has a market capitalization of $151.82 billion, a P/E ratio of 36.20, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the prior year, the firm earned ($0.17) earnings per share. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.42%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 232.43%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.